Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Terns Pharmaceuticals, Inc. Director's Dealing 2025

Jun 30, 2025

32559_dirs_2025-06-30_adeee702-3473-4647-9379-dedd5b26d2ff.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-06-27

Reporting Person: Gengos Andrew (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-06-27 Common Stock P 5000.00 $3.9267 Acquired 20000.00 Direct
2025-06-27 Common Stock P 5000.00 $3.9299 Acquired 25000.00 Direct